Company Performance Metrics
Avinash Desai: Chief Medical Officer- Paul Diamond: Vice President, Patent and Legal Counsel
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies for life threatening diseases using its alpha particle immunotherapy platform and other related technologies. The company’s principal product candidates include Actimab-A, a Phase I/II clinical trial monoclonal antibody for the treatment of acute
myeloid leukemia in elderly patients; and Iomab-B that has completed a Phase I/II design trial used to condition the bone marrow of patients by destroying blood cancer cells in their bone marrow. It also offers BC8-Y-90 and BC8-SA product candidates, which are in physician sponsored clinical phase I trials at the Fred Hutchinson Cancer Research Center. The company was founded in 2000 and is based in New York, New York.
